Zoetis Inc. (0M3Q.L)
USD 148.98
(1.16%)
USD 148.98
(1.16%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2.34 Billion USD | 10.88% |
| 2022 | 2.11 Billion USD | 3.78% |
| 2021 | 2.03 Billion USD | 24.36% |
| 2020 | 1.63 Billion USD | 9.2% |
| 2019 | 1.5 Billion USD | 5.04% |
| 2018 | 1.42 Billion USD | 65.28% |
| 2017 | 864 Million USD | 5.24% |
| 2016 | 821 Million USD | 142.18% |
| 2015 | 339 Million USD | -41.85% |
| 2014 | 583 Million USD | 15.67% |
| 2013 | 504 Million USD | 15.6% |
| 2012 | 436 Million USD | 77.96% |
| 2011 | 245 Million USD | 122.73% |
| 2010 | 110 Million USD | 210.0% |
| 2009 | -100 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 624 Million USD | 4.17% |
| 2024 Q1 | 599 Million USD | 14.1% |
| 2024 Q3 | 682 Million USD | 9.29% |
| 2023 Q2 | 671 Million USD | 21.56% |
| 2023 FY | 2.34 Billion USD | 10.88% |
| 2023 Q1 | 552 Million USD | 19.74% |
| 2023 Q3 | 596 Million USD | -11.18% |
| 2023 Q4 | 525 Million USD | -11.91% |
| 2022 Q1 | 595 Million USD | 43.72% |
| 2022 FY | 2.11 Billion USD | 3.78% |
| 2022 Q4 | 461 Million USD | -12.85% |
| 2022 Q3 | 529 Million USD | 0.0% |
| 2022 Q2 | 529 Million USD | -11.09% |
| 2021 Q4 | 414 Million USD | -25.0% |
| 2021 Q2 | 512 Million USD | -8.41% |
| 2021 FY | 2.03 Billion USD | 24.36% |
| 2021 Q3 | 552 Million USD | 7.81% |
| 2021 Q1 | 559 Million USD | 55.71% |
| 2020 Q4 | 359 Million USD | -25.05% |
| 2020 FY | 1.63 Billion USD | 9.2% |
| 2020 Q1 | 423 Million USD | 10.16% |
| 2020 Q2 | 377 Million USD | -10.87% |
| 2020 Q3 | 479 Million USD | 27.06% |
| 2019 Q1 | 312 Million USD | -9.57% |
| 2019 Q4 | 384 Million USD | -11.32% |
| 2019 FY | 1.5 Billion USD | 5.04% |
| 2019 Q3 | 433 Million USD | 16.71% |
| 2019 Q2 | 371 Million USD | 18.91% |
| 2018 Q2 | 384 Million USD | 9.09% |
| 2018 Q1 | 352 Million USD | 334.57% |
| 2018 FY | 1.42 Billion USD | 65.28% |
| 2018 Q4 | 345 Million USD | -0.58% |
| 2018 Q3 | 347 Million USD | -9.64% |
| 2017 Q3 | 298 Million USD | 20.65% |
| 2017 Q1 | 238 Million USD | 54.55% |
| 2017 FY | 864 Million USD | 5.24% |
| 2017 Q4 | 81 Million USD | -72.82% |
| 2017 Q2 | 247 Million USD | 3.78% |
| 2016 Q3 | 239 Million USD | 6.7% |
| 2016 FY | 821 Million USD | 142.18% |
| 2016 Q1 | 204 Million USD | 827.27% |
| 2016 Q2 | 224 Million USD | 9.8% |
| 2016 Q4 | 154 Million USD | -35.56% |
| 2015 FY | 339 Million USD | -41.85% |
| 2015 Q4 | 22 Million USD | -88.36% |
| 2015 Q3 | 189 Million USD | 610.81% |
| 2015 Q2 | -37 Million USD | -122.42% |
| 2015 Q1 | 165 Million USD | 30.95% |
| 2014 FY | 583 Million USD | 15.67% |
| 2014 Q4 | 126 Million USD | -24.1% |
| 2014 Q3 | 166 Million USD | 22.06% |
| 2014 Q1 | 155 Million USD | 47.62% |
| 2014 Q2 | 136 Million USD | -12.26% |
| 2013 Q1 | 140 Million USD | 1500.0% |
| 2013 Q2 | 128 Million USD | -8.57% |
| 2013 Q3 | 131 Million USD | 2.34% |
| 2013 Q4 | 105 Million USD | -19.85% |
| 2013 FY | 504 Million USD | 15.6% |
| 2012 Q4 | -10 Million USD | -106.17% |
| 2012 Q3 | 162 Million USD | -6.36% |
| 2012 FY | 436 Million USD | 77.96% |
| 2012 Q2 | 173 Million USD | 55.86% |
| 2012 Q1 | 111 Million USD | 1133.33% |
| 2011 FY | 245 Million USD | 122.73% |
| 2011 Q1 | 76 Million USD | 0.0% |
| 2011 Q2 | 66 Million USD | -13.16% |
| 2011 Q3 | 94 Million USD | 42.42% |
| 2011 Q4 | 9 Million USD | -90.43% |
| 2010 FY | 110 Million USD | 210.0% |
| 2009 FY | -100 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | 859.86% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 4425.681% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 2749.156% |
| Agilent Technologies, Inc. | 1.24 Billion USD | -89.032% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 765.743% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 632.434% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 1646.337% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 5034.217% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 948.888% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 1079.777% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -1298.193% |
| bluebird bio, Inc. | -211.91 Million USD | 1206.114% |
| Blueprint Medicines Corporation | -506.98 Million USD | 562.342% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 2077.842% |
| Imunon, Inc. | -19.51 Million USD | 12111.288% |
| Adicet Bio, Inc. | -142.65 Million USD | 1743.09% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -2108.404% |
| Dynavax Technologies Corporation | -6.38 Million USD | 36788.058% |
| Editas Medicine, Inc. | -153.21 Million USD | 1629.836% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 408.218% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 1220.202% |
| Exelixis, Inc. | 207.76 Million USD | -1028.198% |
| FibroGen, Inc. | -284.23 Million USD | 924.678% |
| Geron Corporation | -184.12 Million USD | 1373.034% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -732.404% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 2220.135% |
| Illumina, Inc. | -1.16 Billion USD | 301.895% |
| Incyte Corporation | 597.59 Million USD | -292.236% |
| Insmed Incorporated | -749.56 Million USD | 412.714% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 587.124% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 739.937% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 627.884% |
| IQVIA Holdings Inc. | 1.35 Billion USD | -72.607% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 5654.634% |
| Mettler-Toledo International Inc. | 788.77 Million USD | -197.169% |
| Evolus, Inc. | -61.68 Million USD | 3899.951% |
| Myriad Genetics, Inc. | -112 Million USD | 2192.857% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | -838.726% |
| OPKO Health, Inc. | -188.86 Million USD | 1341.111% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 537.332% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -178015.502% |
| Verastem, Inc. | -87.36 Million USD | 2782.935% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 127.142% |
| Waters Corporation | 642.23 Million USD | -264.976% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 35.241% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 60.901% |
| Biogen Inc. | 1.16 Billion USD | -101.878% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 1009.123% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 40.712% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 5355.215% |
| Homology Medicines, Inc. | -53.74 Million USD | 4461.498% |
| Nektar Therapeutics | -276.05 Million USD | 949.103% |
| TG Therapeutics, Inc. | 12.67 Million USD | -18397.475% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 2828.913% |
| Perrigo Company plc | -12.7 Million USD | 18556.693% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 5980.582% |